Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis

Xue Bai, Xue Lin, Jin Song, Jia-han Chang, Li-li Han, Cibo Fan

Medical Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.

Bai X, Lin X, Song J, Chang JH, Han LL, Fan C. Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis. Clinics (Sao Paulo). 2021;76:e2653

Corresponding author. E-mail: baixue_pla@163.com

This study aimed to estimate the incidence of central nervous system (CNS) metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with trastuzumab.

Studies were identified through a literature search of electronic databases. Random-effects meta-analyses were performed to estimate the incidence rate of CNS metastases, trastuzumab therapy duration, and time from trastuzumab therapy to CNS metastasis diagnosis. A meta-analysis of odds ratios was performed to evaluate the significance of a difference in CNS metastasis incidence between patients with and without trastuzumab treatment.

Thirty studies (8121 trastuzumab-treated and 3972 control patients) were included. The follow-up duration was 18.9 months (95% confidence interval [CI]: 13.8, 24.1). The trastuzumab treatment duration was 9.0 months (95% CI: 7.0, 11.0). The median interval between the start of trastuzumab therapy and CNS metastasis diagnosis was 12.2 months (95% CI: 9.5, 14.7). The incidence of CNS metastasis after the start of trastuzumab therapy was 22% (95% CI: 16, 27). The incidence of CNS metastases was significantly higher in trastuzumab-treated than in non-trastuzumab-treated patients (odds ratio: 1.39 [95% CI: 1.06, 1.82], p=0.02). The survival time from the start of the study was 23.4 months (95% CI: 19.7, 27.1) in trastuzumab-treated patients and 18.4 months (95% CI: 12.7, 24.1) in patients treated with control regimens. The survival time after the development of CNS metastases in trastuzumab-treated patients was 19.2 months (95% CI: 15.6, 25.9).

Approximately 22% of patients with HER2-positive MBC who were treated with trastuzumab developed CNS metastases. However, trastuzumab-treated patients had a longer survival than patients who were not treated with trastuzumab.

KEYWORDS: Metastatic Breast Cancer; Central Nervous System; Brain; Metastases; Trastuzumab.

INTRODUCTION

Breast cancer is the second leading cause of cancer-related deaths in women, with a mortality rate of 2.6% in female patients (1). It accounts for 15.3% of all new cancer cases and 7% of all cancer mortalities. It is estimated that approximately 13% of women will be diagnosed with breast cancer during their lifetime (2). Although the prognosis of breast cancer has improved, it is also associated with an increased risk of metastases in the central nervous system (CNS), especially in the brain. Among women with metastatic breast cancer (MBC), 15% to 30% develop CNS metastases, which are associated with poor survival and neurological impairment (3). Generally, CNS metastases develop late in the disease course, usually after the appearance of systemic metastases, and many cases remain undiagnosed. Studies have shown that up to 30% of patients with breast cancer have undiagnosed CNS diseases (4).

The risk factors for the development of brain metastases include young age, high-grade tumors, negative hormone receptor status, more than four lymph node metastases, and human epidermal growth factor receptor-2 (HER2) positivity (3). Progression to the CNS is also frequent in MBC patients with BRCA mutations, especially BRCA2 mutations (5). Approximately 20% of women with breast cancer have a HER2-positive status, which is associated with a poor prognosis (4). Patients with overexpressing HER2 breast cancer have an increased risk of developing CNS metastases (6).

The management of breast cancer usually involves multidisciplinary treatments, including surgical interventions, radiotherapy, radiosurgery, and systemic treatments. The use
of combination drugs and development of novel delivery systems have also improved in recent years. Systemic therapies with cytotoxic and hormonal agents and biologically targeted therapies are the core treatment options for patients with MBC. Immunotherapies also have a promising role in the treatment of MBC, especially in triple-negative and HER2-positive tumors.

Trastuzumab is a HER2-targeted humanized monoclonal antibody. It has been found to be efficacious for HER2-positive MBC and to be beneficial even after the progression of cancer. Trastuzumab was approved for the treatment of HER2-positive MBC in 1998 in the United States and in 2000 in Europe. Later, it was also approved for use as an adjuvant therapy in 2006 and as a neoadjuvant therapy in 2011. Trastuzumab emtansine is formed by the combination of trastuzumab linked with a cytotoxic component comprising a maytansine-derivative microtubule inhibitory agent called mertansine or DM1.

Although trastuzumab treatment improves the survival outcomes of patients with breast cancer, it has been found to be associated with an increased risk of CNS metastases. Many studies have reported the incidence of CNS metastases in patients with MBC during trastuzumab treatment; however, the magnitude of the incidence substantially varies across the studies. Therefore, we performed a systematic review to identify studies reporting the incidence of CNS metastases in patients with HER2-positive MBC treated with trastuzumab and conducted meta-analyses of CNS metastasis incidence and survival rates to obtain refined estimates.

## MATERIALS AND METHODS

### Ethics

All analyses were based on previously published studies; thus, no ethical approval or patient consent was required.

### Inclusion and exclusion criteria

The inclusion criteria for the studies were as follows: (a) evaluating the outcomes of trastuzumab therapy either alone or with other therapies in HER2-positive MBC patient cohorts, (b) reporting the incidence of CNS metastases in trastuzumab-treated patients, (c) comparing the incidence of CNS metastases between trastuzumab-treated patients and patients treated with non-trastuzumab regimens, and (d) reporting the survival outcomes of patients with HER2-positive MBC treated with trastuzumab. The exclusion criteria were as follows: (a) recruiting all patients with CNS metastases at baseline, (b) reporting the CNS metastasis incidence in patients with MBC treated with more than one regimen without differentiating the outcomes of each treatment, (c) reporting baseline CNS metastases but not the incidence during the study, and (d) case reports.

### Literature search

A literature search was conducted in electronic databases (Google Scholar, Ovid, PubMed, and Science Direct). The key terms used were “breast cancer,” “carcinoma,” “metastatic,” “metastasis,” “trastuzumab,” “brain metastases,” “central nervous system metastases,” “incidence,” “progressive,” “progression,” “recurrence,” “response,” “survival,” and “efficacy.” The bibliographies of important research and review articles were also screened. The literature search encompassed original research articles published in English before October 2020.

### Data extraction, synthesis, and statistical analysis

Demographic data, study design, molecular characteristics, treatment and control regimens, follow-up duration, treatment duration, prior therapies, cancer stage, performance status, baseline CNS metastases, CNS metastasis incidence, treatment response, and survival data were extracted from the included studies. Publication bias was assessed with Begg’s test using Kendall’s rank correlation coefficients between the effect estimates and their variances.

To estimate the incidence of CNS metastases, a meta-analysis of proportions was performed with Stata software (Stata Corporation, College Station, TX, USA) using binomial data reported by the individual studies. For variance stabilization, the Freeman-Tukey double arcsine transformation of proportions was incorporated using the exact binomial method. The median overall survival times of trastuzumab-treated and control patients were pooled using a random-effects model by deriving the variance from the study sample sizes. Follow-up periods and trastuzumab treatment periods were also pooled to achieve overall estimates, which were the inverse variance weighted averages of individual study estimates.

To determine the significance of a difference between trastuzumab and control regimens in the incidence of CNS metastases, meta-analyses of odds ratios were performed. To estimate the difference in survival between trastuzumab-treated patients with and without CNS metastases, a meta-analysis of mean differences was performed. Both meta-analyses were performed with the Cochrane Review Manager software (version 5.3; Nordic Cochrane Center, Copenhagen, Denmark). Statistical heterogeneity (inconsistency of outcomes between studies) was estimated using the I² index.

## RESULTS

Thirty studies (13–42) were included (Appendix Figure S1). In these studies, 8121 patients with HER2-positive MBC were treated with trastuzumab with or without chemotherapy, and 3972 control patients received treatments without trastuzumab. Of the included studies, 7 were randomized controlled trials, 1 was a randomized prospective study, 1 was a prospective non-randomized study, and 21 were retrospective studies. According to Begg’s test for publication bias assessment, there was no significant publication bias (adjusted Kendall’s score: 83, standard deviation: 56; p=0.139; Appendix Figure S2). The important characteristics of the included studies are listed in Appendix Table S1.

The percentage of patients with stage IV cancer was 32% (95% confidence interval [CI]: 13, 55). The percentage of estrogen receptor-positive patients was 47% (95% CI: 43, 51) and that of progesterone receptor-positive patients was 38% (95% CI: 32, 43). The percentage of estrogen- and progesterone receptor-positive patients was 43% (95% CI: 31, 55). Trastuzumab was used as first-line therapy in 61% (95% CI: 10, 99) of the patients.

The follow-up duration of this population was 18.9 months (95% CI: 13.8, 24.1), and the duration of trastuzumab treatment was 9.0 months (95% CI: 7.0, 11.0). The median...
interval between the start of trastuzumab therapy and CNS metastasis diagnosis was 12.2 months (95% CI: 9.5, 14.7). The incidence of CNS metastasis in patients with HER2-positive MBC during trastuzumab therapy was 22% (95% CI: 16, 27) (Figure 1). The incidence of CNS metastases was significantly higher in patients treated with trastuzumab-based regimens than in patients not treated with trastuzumab (odds ratio: 1.39 [95% CI: 1.06, 1.82], \( p = 0.02 \); Figure 2).

The median survival time from the start of trastuzumab therapy in patients with MBC treated with trastuzumab was 23.4 months (95% CI: 19.7, 27.1), whereas the survival time after treatment with control regimens was 18.4 months (95% CI: 12.7, 24.1). The survival time after the development of CNS metastases in trastuzumab-treated patients was 19.2 months (95% CI: 15.6, 25.9) (Figure 3). The survival time from the start of trastuzumab therapy was significantly shorter in patients with CNS metastases than in patients who did not develop CNS metastasis (mean difference: 10.9 months [95% CI: 8.4, 13.3], \( p < 0.0001 \); Appendix Figure S3).

In meta-regression analyses, the incidence rate of CNS metastases was not statistically significantly associated with study duration (meta-regression coefficient [MC]: 0.005 [95% CI: −0.003, 0.013], \( p = 0.194 \)), trastuzumab treatment duration (MC: −0.0004 [95% CI: −0.010, 0.009], \( p = 0.922 \)), age (−0.002 [95% CI: −0.012, 0.008], \( p = 0.672 \)), baseline CNS metastases (MC: −0.0004 [95% CI: −0.001, 0.0002], \( p = 0.256 \)), estrogen receptor positivity (MC: −0.006 [95% CI: −0.022, 0.010], \( p = 0.438 \)), progesterone receptor positivity (MC: 0.002 [95% CI: 0.012, 0.016], \( p = 0.774 \)), or study publication year (MC: −0.00005 [95% CI: −0.0002, 0.0001], \( p = 0.367 \)). However, the incidence rate of CNS metastases was significantly

### Table 1 - Forest plot showing the results of the meta-analysis of the incidence rate of CNS metastases in patients with HER2-positive MBC treated with trastuzumab.

| Study                     | ES (95% CI)          | % Weight |
|---------------------------|----------------------|----------|
| Awada et al. (13)         | 0.31 (0.26, 0.37)    | 3.34     |
| Bartsch et al. (14)       | 0.38 (0.24, 0.53)    | 2.86     |
| Bartsch et al. (15)       | 0.41 (0.26, 0.59)    | 2.69     |
| Bendell et al. (16)       | 0.34 (0.27, 0.43)    | 3.24     |
| Blackwell et al. (17)     | 0.06 (0.03, 0.11)    | 3.27     |
| Burnstein et al. (18)     | 0.09 (0.04, 0.20)    | 3.00     |
| Burnstein et al. (19)     | 0.10 (0.07, 0.14)    | 3.34     |
| Canney et al. (20) PCI    | 0.35 (0.19, 0.54)    | 2.63     |
| Canney et al. (20) PCI    | 0.20 (0.08, 0.39)    | 2.60     |
| Chargari et al. (21)      | 0.23 (0.11, 0.40)    | 2.73     |
| Claryon et al. (22)       | 0.25 (0.17, 0.34)    | 3.18     |
| Danese et al. (23)        | 0.22 (0.19, 0.26)    | 3.41     |
| Duchnowska et al. (24)    | 0.35 (0.27, 0.43)    | 3.27     |
| Errante et al. (25)       | 0.50 (0.27, 0.73)    | 2.19     |
| Gori et al. (26)          | 0.28 (0.21, 0.36)    | 3.24     |
| Harbeck et al. (27)       | 0.11 (0.07, 0.17)    | 3.30     |
| Kroep et al. (28)         | 0.04 (0.02, 0.06)    | 3.40     |
| Lai et al. (29)           | 0.48 (0.37, 0.59)    | 3.13     |
| Lower et al. (30)         | 0.25 (0.17, 0.35)    | 3.16     |
| Metro et al. (31)         | 0.32 (0.22, 0.44)    | 3.09     |
| Montagna et al. (32)      | 0.40 (0.30, 0.51)    | 3.13     |
| Montemurro et al. (33)    | 0.13 (0.02, 0.15)    | 3.45     |
| Park et al. (34)          | 0.38 (0.29, 0.47)    | 3.22     |
| Pivot et al. (35)         | 0.05 (0.03, 0.08)    | 3.35     |
| Puente Vázquez et al. (36)| 0.20 (0.13, 0.29)    | 3.15     |
| Romond et al. (37)        | 0.02 (0.01, 0.03)    | 3.44     |
| Shum et al. (38)          | 0.24 (0.14, 0.39)    | 2.88     |
| Stemmler et al. (39)      | 0.31 (0.24, 0.39)    | 3.26     |
| Swain et al. (40) TD      | 0.13 (0.10, 0.16)    | 3.39     |
| Swain et al. (40) TDP     | 0.14 (0.11, 0.17)    | 3.39     |
| Witzel et al. (41)        | 0.39 (0.28, 0.50)    | 3.11     |
| Yau et al. (42)           | 0.26 (0.18, 0.37)    | 3.16     |
| Overall (I-squared=96.46%, \( p = 0.00 \)) | 0.22 (0.17, 0.28) | 100.00 |

**Figure 1** - Forest graph showing the results of the meta-analysis of the incidence rate of CNS metastases in patients with HER2-positive MBC treated with trastuzumab.
inversely associated with the study sample size (MC: 0.0001 [95% CI: 0.0002, 0.00002], p=0.013) independently (Figure 4) and in multivariate analyses with all of the above explanatory variables.

**DISCUSSION**

In this meta-analysis, we found that approximately 22% of patients treated with trastuzumab, either alone or in combination with chemotherapy, developed CNS metastases approximately 1 year after the start of trastuzumab therapy. The duration of trastuzumab therapy was approximately 9 months. The incidence of CNS metastases was significantly higher in trastuzumab-treated patients than in control patients. The survival time from the start of trastuzumab and control therapies was approximately 23 and 18 months, respectively. The survival time after the development of CNS metastases in trastuzumab-treated patients was approximately 19 months.

In a multicenter, prospective, observational cohort study of about 1000 patients with HER2-positive MBC with trastuzumab as the predominant treatment agent, 9% of the patients had CNS metastases at MBC diagnosis and 22% additional patients developed CNS metastases after a median follow-up of 28 months (43). These outcomes provide further support to the findings of the present study. However, a considerable variability was observed in the incidence of CNS metastases (range: 2%-50%) in the included studies, and a significant inverse relationship was found between the study sample size and CNS incidence.

Krop et al. (28) found a similar incidence of CNS metastases in the trastuzumab and capcitabine groups and noted that the absolute risk of CNS progression was higher in patients with baseline metastases (28). Moreover, because the survival of patients with CNS metastases at baseline remains shorter than those without baseline CNS metastases (33), the number of patients with baseline metastases can influence the incidence rate of CNS metastases in a study. Young age and an estrogen receptor-negative status are also considered risk factors for CNS metastases (44,45).

Although we found a statistically significantly higher incidence of CNS metastases in patients with HER2-positive MBC treated with trastuzumab than in those treated with control regimens, this meta-analysis needs to be elaborated. Seven of the 10 included studies in this meta-analysis did not find a statistically significant difference in the CNS metastasis incidence between the trastuzumab and control regimens. Two studies found a higher incidence of CNS metastases with the control regimen than with the trastuzumab regimen. In this meta-analysis, the overall incidence of CNS metastases in control patients was 14% (95% CI: 7, 22) in the trastuzumab group and 12% (95% CI: 4, 22) in the control group.

Metro et al. (31) reviewed 69 patients with MBC treated with trastuzumab, of whom 22 developed CNS metastases during the treatment. Of the patients who developed CNS metastases, 10 continued trastuzumab and 10 discontinued trastuzumab to receive second-line chemotherapy and radiotherapy. The median time to progression in patients who continued trastuzumab was 10 months (95% CI: 1, 21); however, it was 7 months (95% CI: 1, 15) in patients who stopped trastuzumab (31). Swain et al. (40) found a longer time to the development of CNS metastases in pertuzumab–trastuzumab–docetaxel-treated patients than in trastuzumab–docetaxel-treated patients. Such observations support the growing evidence of the effectiveness of trastuzumab in preventing or delaying progression to the CNS.

We found that the survival time of patients (with or without CNS metastases) treated with trastuzumab was approximately 2 years, whereas the approximate survival time of patients treated with non-trastuzumab therapies was 18 months. In trastuzumab-treated patients, the survival time after the diagnosis of CNS metastasis was approximately 19 months. A difference in the survival time after CNS metastasis of as much as 14 months has been observed between patients with and without trastuzumab treatment (46). This shows that trastuzumab offers an overall benefit to patients with HER2-positive MBC despite conferring a marginally increased risk of CNS metastases. This appears to have practical implications, as evident from the continued use of trastuzumab therapy even after cancer progression in several trials (27).

This study had some limitations. The detection of a high statistical heterogeneity in some analyses is an important
Consideration. The wide range of CNS metastasis incidence and confounders such as age, estrogen/progesterone receptor status, and follow-up durations may have affected the outcomes. We could not perform a quality assessment of the included studies because of the varying study designs. For some variables, such as performance status, cancer stage, and progression-free survival, fewer data were available. In addition, insufficient information was available for performing subgroup analyses with respect to the combinations used in trastuzumab regimens.

CONCLUSIONS

Approximately 22% of patients with HER2-positive MBC developed CNS metastases during trastuzumab treatment, although the range was rather wide and the incidence of CNS metastases increased with decreasing study population size, indicating that the actual incidence may be lower than that estimated in the present study. However, trastuzumab-treated patients had a longer survival than patients treated with non-trastuzumab therapies.
Figure 4 - Meta-regression scatterplot showing the relationship of the incidence rate of CNS metastases in patients with HER2-positive MBC treated with trastuzumab to the study sample size.

**AUTHOR CONTRIBUTIONS**

Bai X wrote the manuscript. Lin X and Song J collected the data. Chang JH, Han LL and Fan C analyzed the data.

**REFERENCES**

1. American Cancer Society. About Breast Cancer. https://www.cancer.org/cancer/breast-cancer/about.html [Accessed November 15th, 2020]
2. National Institutes of Health. National Cancer Institute. Surveillance, Epidemiology, and Results Program. Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html [Accessed November 15th, 2020]
3. Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016;18(1):8. https://doi.org/10.1186/s13058-015-0665-1
4. Piekowsk T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol. 2010;21(5):917-24. https://doi.org/10.1093/annonc/mdp535
5. Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. 2020;126(2):271-90.  https://doi.org/10.1002/cncr.32940
6. Bartolotti M, Franceschi E, Brandes AA. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol. 2013;9(11):1653-64. https://doi.org/10.2217/fon.13.90
7. Fissusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7(1):3-23. https://doi.org/10.2174/2211738507666190122111224
8. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyrilakis S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102(7): 456-63.  https://doi.org/10.1093/jnci/djp029
9. Sugi T. Immunotherapy for metastatic breast cancer. Chin Clin Oncol. 2018;7(3):28. https://doi.org/10.21037/cco.2018.05.05
10. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh PE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12): 1999-2006. https://doi.org/10.1200/JCO.2008.19.6618
11. Blackwell K, Gilgrov J, Jacobs L, Twelves C. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Clin Breast Cancer. 2018;18(2):95-113. https://doi.org/10.1016/j.clbc.2018.01.006
12. Barok M, Joenou H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209. https://doi.org/10.1186/bcr3621
13. Awada A, Colomer R, Inoue K, Bondarenko I, Badve RA, Demetriou G, et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic HER2-Positive Breast Cancer: The NERBRT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1587-64. https://doi.org/10.1001/jamaoncol.2016.0237
14. Bartsch R, Wenzel C, Altorjai G, Pluschung U, Radas M, Mader RM, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8. https://doi.org/10.1200/JCO.2007.11.9776
15. Bartsch R, Wenzel C, Gampenrieder SP, Pluschung U, Altorjai G, Rudas M, et al. Trastuzumab and gencitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(5):903-10. https://doi.org/10.1007/s00280-008-0682-1
16. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972-7. https://doi.org/10.1002/cncr.11436
17. Blackwell K, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30. https://doi.org/10.1200/JCO.2008.21.4437
18. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21(15): 2889-95. https://doi.org/10.1200/JCO.2003.02.018
19. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005;16(11):1772-7. https://doi.org/10.1093/annonc/mdi371
20. Canney P, Murray E, Dixon-Hughes J, Levesley LA, Paul J. A Prospective Randomised Phase III Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated with Trastuzumab for Metastatic Breast Cancer - Anglo Celtic VII. Clin Oncol (R Coll Radiol). 2015;27(8):460-4. https://doi.org/10.1016/j.clon.2015.04.033

21. Chargari C, Idriess HR, Pierje JG, Bollet MA, Diéras V, Campaña F, et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011;81(5):631-6. https://doi.org/10.1016/j.ijrobp.2010.06.057

22. Clayton AJ, Dansoon S, Jolly S, Ryder WD, Burt PA, Stewart AL, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):439-43. https://doi.org/10.1038/sj.bjc.6601970

23. Danese MD, Lindquist K, Doan J, Lalla D, Brummer M, Griffiths RI. Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. J Cancer Epidemiol. 2012;2012:819210.

24. Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad OJ. Central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113-9. https://doi.org/10.1093/annonc/mdu486

25. Errante D, Bernardi D, Bianco A, Salvagno L, Brain metastases in patients receiving trastuzumab-containing therapy. Oncologist. 2012;17(1):26-35. https://doi.org/10.1634/theoncologist.2011-0212

26. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007;12(7):766-73. https://doi.org/10.1634/theoncologist.12-7-766

27. Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016;17(3):357-66. https://doi.org/10.1016/S1470-2045(15)00546-9

28. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial (\(\dagger\)). Ann Oncol. 2020;31(10):1350-8. https://doi.org/10.1016/j.annonc.2020.06.020

29. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894-900. https://doi.org/10.1038/sj.bjc.6604941

30. Pivot X, Manikhas A, urawsbi K, Chmielowksa E, Karaszewska B, Allerton R, et al. CERECEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2015;33(14):1564-73. https://doi.org/10.1200/JCO.2014.57.1794

31. Puente Vázquez J, López-Tarruella Cobo S, García-Sáenz JA, Casado Herráez A, Moreno Antón F, Sampedro Cimeno T, et al. Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transl Oncol. 2006;8(1):50-3. https://doi.org/10.1007/s12094-006-0095-8

32. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1674-84. https://doi.org/10.1056/NEJMoa051222

33. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer. 2004;40(3):379-82. https://doi.org/10.1016/j.ejca.2003.09.018

34. Stemmler HJ, Kahler S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with breast metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219-25. https://doi.org/10.1016/j.breast.2005.04.017

35. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-21. https://doi.org/10.1093/annonc/mdu133

36. Witzel I, Kantelhardt EJ, Milde-Langosch K, Ihnen M, Zeitz J, Harbeck N, et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. Onkologie. 2011;34(6):304-8. https://doi.org/10.1002/sj.o.123879

37. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45(2):196-201. https://doi.org/10.1080/028418605008486630

38. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Bruksky A, et al. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019;25(8):2433-41. https://doi.org/10.1158/1078-0432.CCR-18-2366

39. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol). 2004;16(5):345-9. https://doi.org/10.1016/j.clon.2004.03.012

40. Rudat V, El-Sweileh M, Brune-Elber B, Nor A, Almasri N, Altuwajri S, et al. Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. BMC Cancer. 2014;14:289. https://doi.org/10.1186/1471-2407-14-289

41. Bruksky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2013;19(14):4834-43. https://doi.org/10.1158/1078-0432.CCR-12-2962
### APPENDIX

#### Table S1 - Important characteristics of the included studies.

| Study          | nT  | nC  | Trastuzumab regimen | Control regimen | Study duration (months) | Treatment duration (months) | Age (years) |
|----------------|-----|-----|---------------------|-----------------|-------------------------|-----------------------------|-------------|
| Awada 2016     | 237 | 242 | T–PAC               | Neratinib–PAC   | 23 (IQR: 13.8–32.3)     | 11.5 (IQR: 5.8–18)          | 55 (IQR: 47–62) |
| Bartsch 2007   | 40  |     | T–CAP               |                 | 19 (range: 3–42)        | 58.5 (range: 29–73)         | 60 (range: 29–83) |
| Bartsch 2008   | 29  |     | T–GEMB              |                 | 23                      | 7.1                         | 50          |
| Bendell 2003   | 122 |     | T–CT                |                 | 5.6 (range: 0.5–16)     | 54.5 (range: 29–82)         | 53 (SD: 11)  |
| Blackwell 2010 | 146 | 146 | T–lapatinib         | Lapatinib       | 18.5 (range: 1.3–65.1)   | 49 (range: 36–65)           |             |
| Burnstein 2005 | 54  |     | T–VINO              |                 | 13.9 (range: 0.5–21)    | 54.4 (range: 29–82)         | 53 (SD: 11)  |
| Burnstein 2005 | 234 | 230 | T–PAC/DOX/CPD       | PAC/DOX/CPD     | 9.3 (IQR: 7.3–15.6)     | 4.7 (IQR: 2.1–7.4)          | 53.1 (SD: 12.3) |
| Canney 2015    | 51  |     | T–taxane/PC         |                 | 30.7 (range: 3.2–47.5)  | 19.1                        | 53 (range: 25–84) |
| Chargani 2003  | 31  |     | T–RT                |                 | 28.5 (range: 0.5–16)    | 54.8 (range: 29–82)         | 47.3 (SD: 10.3) |
| Clayton 2004   | 93  |     | T–CT                |                 | 28 (range: 2–167)       | 48 (range: 28–79)           |             |
| Danese 2012    | 562 |     | T–CT                |                 | 13.9 (IQR: 6.6–23.7)    | 8 (range: 0–52)             | 48 (range: 23–76) |
| Duchnowska 2012| 142 |     | T–taxane/VINO/CAP    |                 | 29 (range: 1–115)       | 10 (range: 1–115)           | 53 (range: 25–79) |
| Errante 2007   | 14  |     | T–CT                |                 | 35.3                     | 52 (range: 26–79)           |             |
| Gori 2007      | 122 |     | T–CT                |                 | 20.6 (range: 0–50)      | 5.1 (range: 1–46)           | 54.4 (26–88) |
| Krop 2004      | 495 | 496 | T–lapatinib         | Lapatinib–CAP   | 9.3 (IQR: 7.3–15.6)     | 4.7 (IQR: 2.1–7.4)          | 53.1 (SD: 12.3) |
| Lai 2004       | 79  | 264 | T–CT                | CT              | 17.8 (range: 0.2–51)    | 50 (range: 29–82)           |             |
| Lower 2003     | 87  | 190 | T–CT                | CT              | 38.7 (range: 0.5–21)    | 54.4 (range: 26–88)         | 48 (range: 25–71) |
| Metro 2015     | 69  |     | T–CT                | CT              | 35.3                     | 52 (range: 26–79)           |             |
| Montagna 2009  | 78  |     | T–CT                | CT              | 20.6 (range: 0–50)      | 5.1 (range: 1–46)           | 54.4 (26–88) |
| Montemurro 2020| 2002|     | T–CAP               | Lapatinib–CAP   | 9.3 (IQR: 7.3–15.6)     | 4.7 (IQR: 2.1–7.4)          | 53.1 (SD: 12.3) |
| Park 2009      | 111 | 140 | T–CT                | CT              | 17.8 (range: 0.2–51)    | 50 (range: 29–82)           |             |
| Povit 2015     | 250 |     | T–CAP               | Lapatinib–CAP   | 28.5 (range: 0–16)      | 48 (range: 25–71)           |             |
| Puente Vázquez 2006 | 86 |     | T–CT                | CT              | 38.7 (range: 0.5–21)    | 50.5 (range: 26–76)         |             |
| Romond 2005    | 1672| 1679| T–PAC/DOX/CPD       | PAC/DOX/CPD     | 24                       | 13                          |             |
| Shumeli 2004   | 47  |     | T–CT                | CT              | 38.7 (range: 0.5–21)    | 50.5 (range: 26–76)         |             |
| Swain 2004     | 30  |     | T–DOC/pertuzumab    |                 | 24 (range: 1–98)        | 11 (range: 1–50)            | 55 (31–84)  |
| You 2006       | 87  |     | T–CT                | CT              | 24 (range: 1–98)        | 11 (range: 1–50)            | 55 (31–84)  |

Abbreviations: CAP, capecitabine; CPD, cyclophosphamide; CT, chemotherapy; DOC, docetaxel; DOX, doxorubicin; ECOG PS, Eastern Ontario Cooperative Group performance status; GEMB, gemcitabine; IQR, interquartile range; PAC, paclitaxel; PCI, prophylactic cranial irradiation; RT, radiotherapy; SD, standard deviation; T, trastuzumab; VINO, vinorelbine; ER, estrogen receptor; PR, progesterone receptor; KPS, Karnofsky Performance Status.
Figure S1 - Flowchart of the screening and selection of the included studies.
Figure S2 - Funnel plot showing the results of Begg's test for publication bias assessment.

Figure S3 - Forest graph showing the results of the meta-analysis of the survival difference between MBC patients with and without CNS metastases.